Abstract

The discovery of the G protein-coupled estrogen receptor GPER (also GPR30) and the resulting development of selective chemical probes have revealed new aspects of estrogen receptor biology. The potential clinical relevance of this receptor has been suggested from numerous studies that have identified GPER expression in breast, endometrial, ovarian and other cancers. Thus GPER can be considered a candidate biomarker and target for non-invasive imaging and therapy. We have designed and synthesized a series of organometallic tricarbonyl-rhenium complexes conjugated to a GPER-selective small molecule derived from tetrahydro-3H-cyclopenta[c]quinoline. The activity and selectivity of these chelates in GPER-mediated signaling pathways were evaluated. These results demonstrate that GPER targeting characteristics depend strongly on the structure of the chelate and linkage. Ethanone conjugates functioned as agonists, a 1,2,3-triazole spacer yielded an antagonist, and derivatives with increased steric volume exhibited decreased activities. Promising GPER selectivity was observed, as none of the complexes interacted with the nuclear estrogen receptors. Radiolabeling with technetium-99m in aqueous media was efficient and gave radioligands with high radiochemical yields and purity. These chelates have favorable physicochemical properties, show excellent stability in biologically relevant media, exhibit receptor specificity and are promising candidates for continuing development as diagnostic imaging agents targeting GPER expression in cancer.

Highlights

  • IntroductionThe genomic roles of the nuclear estrogen receptors ERa and ERb have been characterized in greatest detail

  • Estrogens are involved in a diverse array of physiological responses

  • The recent identification of the involvement of a G protein-coupled estrogen receptor GPR30 (IUPHAR designation: GPER) in tumor signaling pathways and studies demonstrating the prognostic value of assessing GPER expression suggest GPER may serve as a potentially important biomarker and therapeutic target in cancer [5,6,7,8,9]

Read more

Summary

Introduction

The genomic roles of the nuclear estrogen receptors ERa and ERb have been characterized in greatest detail. ERa, and to some extent ERb, are important drug targets because of their roles in development, reproduction, skeletal physiology and the nervous, cardiovascular, and immune systems. Estrogen-responsiveness constitutes a major determinant of therapy selection and prognosis in breast cancer with both genomic and non-genomic pathways regulating tumor biology [1,2,3,4]. The recent identification of the involvement of a G protein-coupled estrogen receptor GPR30 (IUPHAR designation: GPER) in tumor signaling pathways and studies demonstrating the prognostic value of assessing GPER expression suggest GPER may serve as a potentially important biomarker and therapeutic target in cancer [5,6,7,8,9]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.